290 related articles for article (PubMed ID: 38672492)
1. Innate Immunity and MASLD.
Meyer M; Schwärzler J; Jukic A; Tilg H
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672492
[TBL] [Abstract][Full Text] [Related]
2. Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications.
Yu L; Gao F; Li Y; Su D; Han L; Li Y; Zhang X; Feng Z
Biomed Pharmacother; 2024 Jun; 175():116724. PubMed ID: 38761424
[TBL] [Abstract][Full Text] [Related]
3. The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease.
Sawada K; Chung H; Softic S; Moreno-Fernandez ME; Divanovic S
Cell Metab; 2023 Nov; 35(11):1852-1871. PubMed ID: 37939656
[TBL] [Abstract][Full Text] [Related]
4. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
[TBL] [Abstract][Full Text] [Related]
5. The pathophysiology of MASLD: an immunometabolic perspective.
Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H
Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
Aggeletopoulou I; Tsounis EP; Triantos C
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
[TBL] [Abstract][Full Text] [Related]
7. Hepatic NLRP3-Derived Hsp70 Binding to TLR4 Mediates MASLD to MASH Progression upon Inhibition of PP2A by Harmful Algal Bloom Toxin Microcystin, a Second Hit.
Roy S; Saha P; Bose D; Trivedi A; More M; Xiao S; Diehl AM; Chatterjee S
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003543
[TBL] [Abstract][Full Text] [Related]
8. Roles of immune dysregulation in MASLD.
Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H
Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736
[TBL] [Abstract][Full Text] [Related]
9. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Diagnostic Utility of Selected Serum Adipokines and Cytokines in Subjects with MASLD-A Pilot Study.
Zyśk B; Ostrowska L; Smarkusz-Zarzecka J; Orywal K; Mroczko B; Cwalina U
Nutrients; 2024 May; 16(9):. PubMed ID: 38732626
[TBL] [Abstract][Full Text] [Related]
11. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
Takahashi Y; Dungubat E; Kusano H; Fukusato T
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
[TBL] [Abstract][Full Text] [Related]
12. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
[TBL] [Abstract][Full Text] [Related]
13. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD).
Benedé-Ubieto R; Cubero FJ; Nevzorova YA
Gut Microbes; 2024; 16(1):2331460. PubMed ID: 38512763
[TBL] [Abstract][Full Text] [Related]
14. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
15. Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines.
Pezzino S; Luca T; Castorina M; Puleo S; Latteri S; Castorina S
Life (Basel); 2024 Jan; 14(1):. PubMed ID: 38255708
[TBL] [Abstract][Full Text] [Related]
16. Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease.
Mak AL; Wassenaar N; van Dijk AM; Troelstra M; Houttu V; van Son K; Driessen S; Zwirs D; van den Berg-Faay S; Shumbayawonda E; Runge J; Doukas M; Verheij J; Beuers U; Nieuwdorp M; Cahen DL; Nederveen A; Gurney-Champion O; Holleboom A
JHEP Rep; 2024 Mar; 6(3):100998. PubMed ID: 38379586
[TBL] [Abstract][Full Text] [Related]
17. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
[TBL] [Abstract][Full Text] [Related]
18. Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution.
Yu W; Zhang Y; Sun L; Huang W; Li X; Xia N; Chen X; Wikana LP; Xiao Y; Chen M; Han S; Wang Z; Pu L
Metabolism; 2024 Jun; 155():155911. PubMed ID: 38609037
[TBL] [Abstract][Full Text] [Related]
19. The "Domino effect" in MASLD: The inflammatory cascade of steatohepatitis.
Mladenić K; Lenartić M; Marinović S; Polić B; Wensveen FM
Eur J Immunol; 2024 Apr; 54(4):e2149641. PubMed ID: 38314819
[TBL] [Abstract][Full Text] [Related]
20. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
